Pharming Group Nv · EURONEXT:PHARM
Pharming Group Nv — Shareholder Meeting (May 2012)
16 slides from Pharming Group Nv's shareholder meeting presentation, May 14, 2012
Slide 1: Annual General Meeting of Shareholders
Annual General Meeting of Shareholders May 14, 2012 Sijmen de Vries, CEO Karl Keegan, CFO 1
Slide 2: Agenda
Agenda • Key Developments 2011 • Corporate Governance Improvements • Operational review • Financial review • Outlook 2
Slide 3: Key developments in 2011
Key developments in 2011 Expansion of geographical coverage for Ruconest® Received RTF from FDA; “recovery” through SPA agreement with the FDA on Phase III trial needed to support regulatory approval for Rhucin® Signing of service agreement for development of Factor VIII transgenic rabbits Enh
Slide 4: Corporate Governance Improvements in 2011
Corporate Governance Improvements in 2011 Implementation of Implementation of Implementation of Financial Monthly Reports new Budget Plan Management Information System Implementation of a Implementation of a Implementation of new Risk new Chart of new Contract Cover Assessment Plan Authority Sheet 4
Slide 5: The Company's Strategic Focus
The Company’s Strategic Focus Develop innovative products for diseases with • Commercial focus is primarily the specialty high unmet medical pharmaceutical markets needs Pharming aims to cover • From drug development to commercialisation the entire value chain Establish international • Continue to p
Slide 6: Pharming's plan to expand and de-risk
Pharming’s plan to expand and de-risk Build on recombinant C1-inhibitor (Ruconest®/ Rhucin®) franchise • Further extension of geographical coverage • Evaluate prophylactic HAE therapy • Phase II paediatric study has been initiated • Additional potential indications: Ischemia Reperfusion Injury (IRI)
Slide 7: Current Pipeline
Current Pipeline Indication R&D Pre Phase I Phase II Phase III Registration Market Clinical Ruconest® / Rhucin® Ruconest® (rhC1INH) Hereditary Angioedema (Europe) Rhucin® (rhC1INH) Hereditary Angioedema (US) rhC1INH Ischemia Reperfusion Injury (IRI) indications Delayed Graft Function rhC1INH (Kidney
Slide 8: Ruconest/Rhucin commercial partners to date
Ruconest®/ Rhucin® commercial partners to date 8
Slide 9: Pharming's potential through the validated transgenic expression platform
Pharming’s potential through the validated transgenic expression platform Our engine of value Relevant for most Expression and high creation therapeutic proteins yields Complex proteins of Seeking high quality with Often achieving collaborations relatively high yields significantly higher expression
Slide 10: Key Financial Data
Key Financial Data 10
Slide 11: Statement of financial position 2011: Key data
Statement of financial position 2011: Key data Amounts in €M FY 11 FY 10 Non current assets 10.5 7.9 Cash & equivalents 5.1 10.5 Other current assets 9.1 18.9 Total assets 24.7 37.3 Deferred income 17.3 19.0 Convertible bonds - - Other liabilities 8.6 8.2 Total equity (1.2) 10.1 11
Slide 12: Statement of income 2011: Key data
Statement of income 2011: Key data In €M FY 11 FY 10 Revenues 3.2 1.1 Other operating costs (21.7) (22.3) Financial income 1.0 - Other income/expenses (0.4) (16.5) Net loss from continuing operations (17.8) (37.7) Net loss from discontinued operations 0.6 (18.7) Total net loss (17.2) (56.4) 12
Slide 13: Statement of cash flows 2011: Key data
Statement of cash flows 2011: Key data In €M FY 11 FY 10 Net cash used in operating activities (16.9) (3.2) Net cash from/used in investment (1.1) (0.9) activities Net cash from financing activities 12.7 12.9 13
Slide 14: Financial outlook
Financial outlook No full guidance for expected financial results in 2012 Expecting to receive two development milestones • US$ 10.0 M upon successful readout of Study 1310 • US$ 5.0 M upon acceptance of the BLA filing by the FDA • Expected to being able to recognise milestones immediately Pursuing
Slide 15: Objectives and value drivers in 2012
Objectives and value drivers in 2012 Successful read-out of Submit BLA study 1310 Additional commercialisation deals on Ruconest franchise New platform deal Q1 Q2 Q3 Q4 •Support partners in commercialisation endeavours •Improve visibility amongst investors and other market participants 15
Slide 16: Conestat alfa
Conestat alfa For intravenous use. One vial contains 2100 U of conestat alfa, corresponding to 2100 U/14 ml after reconstitution, or a concentration of 150 U/ml. Excipients: Sucrose, Sodium citrate (E331), Citric acid (E330). Do not store above 25°C. Store in the original package in order to protect